Caribou Biosciences Inc

CRBU

Company Profile

  • Business description

    Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

  • Contact

    2929 7th Street
    Suite 105
    BerkeleyCA94710
    USA

    T: +1 510 982-6030

    https://www.cariboubio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    97

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,071.4094.00-1.03%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,509.76626.52-2.49%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,260.1743.60-0.30%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,955.2089.50-0.99%
SSE Composite Index3,602.5731.78-0.87%

Market Movers